Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
ORGANIZATION FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
-
REGULATORY Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
March 24, 2026
-
BUSINESS Tremfya SC Induction Seen Cutting Hospital Time in UC: Expert
March 24, 2026
-
BUSINESS Padcev-Keytruda under EMA Review for Cisplatin-Eligible Perioperative MIBC
March 24, 2026
-
BUSINESS Nippon Kayaku, GlycoNex Ink Pact on Next-Gen ADC Candidate
March 24, 2026
-
REGULATORY Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
-
BUSINESS Celltrion Wins First Xolair Biosimilar Approval in Japan, Targets May Listing
March 24, 2026
-
BUSINESS Roche-Chugai Drops Emugrobart for SMA, FSHD; Obesity Program to Continue
March 24, 2026
-
REGULATORY Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
-
REGULATORY MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
March 23, 2026
-
ORGANIZATION FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
-
ORGANIZATION JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
-
BUSINESS Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
March 23, 2026
-
REGULATORY Japan Hands Out Orphan Tags to Ianalumab, Bleximenib, and Lots More Drugs
March 23, 2026
-
BUSINESS Chugai Files Device Component of Ranibizumab Eye Implant in Japan
March 23, 2026
-
BUSINESS Shionogi’s Zurzuvae, Kissei’s Yselty Now Available in Japan
March 23, 2026
-
BUSINESS Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
-
REGULATORY Ex-LDP Lawmaker, Pharmacist Jun Matsumoto Dies at 75
March 23, 2026
-
BUSINESS Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
-
ORGANIZATION JPMA Seeks Japan Version of EHDS to Unlock Life-Course Health Data
March 23, 2026
ページ
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…